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Copyright © 2009 JCBN Summary This study was conducted to investigate whether or not a food substitute (Dr.
BAANs®) containing three bioactive components L-arginine, ω-3 polyunsaturated fatty acid,
and ribonucleic acid, supplied orally to 15 overweight patients, may have efficacy to prevent
or improve the metabolic syndrome of these patients. To provide supporting data for this
clinical study, the in vivo fatty acid metabolism of obese mice was analyzed using 125I labeled
15-(p-iodophenyl)-9-methylpentadecanoic acid (9MPA) in the tissues’ lipid pool. After 3
months of intervention, the results showed that there were improvements observed in liver
functions, lipid profiles and metabolic syndrome marker. Significant differences were also
found in the values of blood pressure, body weight, percentage of body fat, and body mass
index. In the animal study, the tissue uptake of 125I-9MPA at 10 min after injection was higher
in obese mice than in the control mice and the treatment with Dr. BAANs® in obese mice
decreased the uptake significantly. The final product metabolite of p-iodophenylacetic acid in
obese mice was increased significantly by the treatment. In conclusion, this food substitute
may have a beneficial effect for the prevention or improvement of metabolic syndrome.
Key Words:L-arginine, ω-3 poly unsaturated fatty acid, ribonucleic acid, metabolic syndrome,
fatty acid metabolism
Introduction
Metabolic syndrome is a cluster of interrelated risk factors
(visceral obesity, hyperlipidemia, hyperglycemia, and
hypertension) that increase susceptibility to cardiovascular
disease and type-2 diabetes. The underlying causes of this
syndrome are obesity, physical inactivity, and genetic factors
[1].
There is general agreement that lifestyle changes pri-
marily focused on weight reduction are the first line
approach in patients with metabolic syndrome. AmongEffect of Dr. BAANs in Humans and Animals
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conventional preventive methods, a low calorie diet
(1500 kcal) and exercise have been practiced as therapy and
preventive methods against metabolic syndrome as typified
by obesity. On the other hand, a low-calorie diet without
exercise will cause a decrease in basal metabolism, which
can cause a lack of nutritional substances and minerals
necessary for the body; therefore, an excessively strict diet
without medical supervision is extremely dangerous [2, 3].
At the 40th meeting of the Japan Society of Adult Diseases
in 2006, Koide et al. [4] addressed a preventive method
against lifestyle diseases in a new concept; Bio Activating
Advanced Nutrients (BAANs) theory. The theory of this
method is not like a conventional diet therapy. It is designed
to stimulate protein synthesis by energy generation in the
process of expediting the burn-off of fatty acids as deriva-
tives of body fat break-down, which promotes the intra-vital
metabolic cycle as a result. The principal ingredients are
three bioactive components: L-arginine, which is present at
high levels in meat, ω-3 poly unsaturated fatty acid, which is
a main component of fish oil, and ribonucleic acid (RNA),
which is found at high numbers in beer yeast.
Recently, the radio labeled fatty acid tracer 15-(p-
iodophenyl)-9-methylpentadecanoic acid (9MPA) was
developed for metabolic analysis. This tracer is converted
to an intermediate metabolite, 3-methylnonanoic acid
(3MNA), after 3 cycles of β-oxidation. 3MNA continuously
undergoes  α and β-oxidation to yield the metabolite p-
iodophenylacetic acid (PIPA). Therefore, 9MPA is well
suited to study fatty acid uptake and oxidation in vivo [5, 6].
In this study for assessing fatty acid metabolism in obese,
leptin deficient ob/ob mice were used, which is an animal
model for obesity, insulin resistance, diabetes, and non-
alcoholic steatohepatitis [7]. In ob/ob mice, the absence of
the leptin signaling in the hypothalamus causes obesity due
to increases in food intake and decreases in energy expendi-
ture.
The aims of the present study were to evaluate whether or
not the food substitute (Dr. BAANs®) administered orally in
overweight patients may have efficacy to prevent or improve
metabolic syndrome after 3 months of treatment, and also to
evaluate in vivo fatty acid metabolism in obese mice, and
obese mice treated by this food substitute.
Materials and Methods
Clinical study
Subjects. Fifteen adult patients of both genders partici-
pated in the experiment. All of the patients met the following
inclusion criteria: age 20–60 years old, obesity with body
mass index (BMI) ≥25 kg/m2. The patients met with one or
more of the following criteria: hypertension, hyperglycemia,
hyperlipidemia, or abnormal liver markers. The exclusion
criteria were a history of thyroid disease, current pregnancy,
an unstable medical condition, or the current use of medica-
tions known to affect lipid metabolism, blood pressure,
blood glucose, or any medication known to affect weight or
appetite. The present study was carried out in accordance
with the Declaration of Helsinki and with the prior approval
by the ethical committee of the Bio Research Center of
Niigata City, Japan. The protocol and aim of the study were
fully explained to the participants, who gave their written
consent.
Food substitute. The food substitute (Dr. BAANs®) used
in this study was donated by BBK Bio Corp in Japan. The
validated composition of each sachet was: 1000 mg L-
arginine, 150 mg ω-3-poly unsaturated fatty acid eicosapen-
taenoic acid (EPA) and docosahexaenoic acid (DHA) in the
ratio of 2:1, 280 mg of all kinds of RNA from beer yeast,
420 mg triglyceride, 12.0 g lactoprotein, and 12.0 g carbo-
hydrates. One sachet was solveled into 250 ml drinking
water and contained 170 kcal.
Study design. An evaluation period of 3 months was
determined in order to observe changes in body weight or
body fat percentage, blood pressure level, blood glucose
level, lipid levels, and hepatic function before and after the
substitution of food with Dr. BAANs®. During the study all
participants received counseling for their intake every day as
follows: for breakfast they drank 1 sachet of Dr. BAANs®
(containing 170 Kcal/250 ml). The participants were asked
not to modify their dietary habits for lunch and dinner or
their lifestyle during the whole experimental period. At the
beginning of the study and every month until one month
after withdrawal of the food substitute, blood samples were
taken in the morning, after a 12 h fast and 15 min of rest,
using blood collection tubes in order to observe the initial
and final levels of glucose, triglyceride (TG), total cholesterol
(TC), high density lipoprotein-cholesterol (HDL-C), low
density lipoprotein-cholesterol (LDL-C), and glycosylated
hemoglobin (HbA1c). For adiponectin and plasminogen
activator inhibitor-1 (PAI-1) only the pretreatment levels,
the levels after 3 months of treatment, and the levels 1 month
after withdrawal of the food substitute were measured. Liver
function was also checked by measuring the aspartate
aminotransferase (AST), alanine aminotransferase (ALT),
and gamma glutamyltransferase (γ-GTP) levels at the base-
line, and every month until one month after withdrawal of
the food substitute.
The prevalence of hyperlipidemia, hypertension, hyper-
glycemia, and abnormal levels of liver function were
registered before and after the experimental period. Hyper-
cholesterolemia was defined as having TC levels more than
220 mg/dl, hypo-high density lipoproteinemia was defined
as having HDL-C values lower than 40 mg/dl. Hyper-
triglyceremia was defined as having TG values higher than
150 mg/dl; Hyper-low density lipoproteinemia was defined
as having LDL-C values higher than 140 mg/dl. All theseK. Watanabe et al.
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parameters were defined according to the guidelines of the
Japan Society of Internal Medicine [8]. Hypertension was
defined as having values of systolic blood pressure (SBP)
more than 140 mmHg or diastolic blood pressure (DBP)
more than 90 mmHg according to the Seventh Report of the
Joint National Committee on Prevention, Detection, Evalua-
tion, and Treatment of High Blood Pressure (JNC 7) criteria
[9].
Obesity was defined as BMI values more than 25 kg/m2;
abnormal values for the percentage of body fat was defined
as more than 25%; and abnormal waist circumference was
defined as values more than 85–90 cm according to new
criteria for obesity in Japan from the Japan Society for the
Study of Obesity [10]. Abnormal values of AST, ALT, and
γ-GTP were defined as values more than 40 IU, 35 IU, and
50 IU, respectively. Hyperglycemia was defined as values of
blood glucose more than 110 mg/dl. An HbA1c abnormal
value was defined as value more than 5.8%.
Anthropometric measurements. Waist circumference was
measured midway between the lower rib margin and the iliac
crest in standing position after normal expiration. Height
was measured using a rigid stadiometer. Weight of the
subjects (in light clothing) was measured on a calibrated
balance scale. Percentage of body fat was measured using a
body fat analyzer. BMI was calculated as weight (kg)
divided by height (m) squared (kg/m2). Blood pressure was
measured using a sphygmomanometer by an ausculatory
method.
Laboratory analysis. Blood, for plasma analyses, was
drawn into sterile glass tubes with 100 units of freeze-dried
sodium heparin and centrifuged at 4,000 g for 5 min at 4°C.
TC, TG, LDL-C, and HDL-C concentrations were deter-
mined using standard enzymatic procedures; AST, ALT,
γ-GTP, and glucose levels were measured with enzymatic
kits using spectrophotometric methods. Adiponectin was
measured by ELISA and PAI-1 was measured by an
enzymatic method.
Safety assessments. All adverse events were collected
from participants every month by medical examinations.
Animal study
Materials. 125I-Labeled 9MPA (7.4 GBq/mg), 125I-labeled
3MNA (7.4 GBq/mg), and 125I-labeled PIPA (7.4 GBq/mg)
were donated by Daichii Radioisotope Laboratories Ltd.
(Tokyo, Japan).
Animals. Obese 8-week-old B6V-Lep ob/ob mice (n =6 ) ,
weighing about 48 grams, and 8-week-old C57 Bl/6 mice
(n = 3), weighing about 25 grams, were purchased from
Charles River Laboratories, Kanagawa, Japan. Three of the
B6V-Lep ob/ob mice were treated with Dr. BAANs®. The
C57 Bl/6 mice served as a control group. The animals were
housed three per cage and allowed free access to food and
water ad libitum. Mice were housed in a temperature-
controlled room under a 12-h light dark (7 a.m. to 7 p.m.)
cycle. For the treatment of obese mice, 1 ml / 25 g BW Dr.
BAANs® was given daily for 1 week. The doses of the
present study were selected on the basis of preliminary
studies.
125I Radioactivity in the tissues lipid pool. 125I-9MPA (741
KBq (20 μCi) was injected intravenously into the above 3
groups of mice (control, obese, and obese treated with
Dr. BAANs®). At 10 min after injection, the mice were
sacrificed. Lipid extraction from tissues (myocardium,
skeletal muscle, visceral fat and subcutaneous fat) was
performed according to a modified version of the method
developed by Folch et al. [11]. Briefly, tissue specimens
were homogenized and extracted twice with chloroform/
methanol (2:1, v/v). The resulting organic, aqueous, and
solid phases were separated. Radioactivity distribution in the
organic phase was assayed by thin layer chromatography
(TLC) on a reverse phase plate (C18 Silicagel Spotfil),
together with 125I-labeled standard fatty acids (9MPA,
3MNA, and PIPA).
Statistical analysis
Data are expressed as mean ± SD. Group comparisons
were made by ANOVA, followed by Tukey’s multiple com-
parison test to identify differences among various groups.
p<0.05 was considered statistically significant.
Results
Clinical study
All of the 15 subjects (100%) completed the study.
Another evaluation that was taken from the history of each
subject showed that nothing changed in their dietary habits
and amount of food they ate. The baseline characteristic of
the participants and changes in parameters after treatment
are summarized in Table 1. After 3-months intervention
body weight, BMI (Fig. 1a), and percentage of body fat
were reduced significantly.
In accordance with JNC 7, high blood pressure prevalence
was assessed in total samples before and after treatment with
Dr. BAANs® (Table 2). The results show that the initial
hypertension prevalence was diminished after intervention
in both SBP and DBP values and the reduction of blood
pressure in systolic and diastolic were 7.2 ± 13.3 and
5.0 ± 10.6 mmHg, respectively. In Fig. 1b we showed the
reduction of blood pressure in systolic for each subject.
The prevalence on the abnormal values of liver function
(AST, ALT, and γGTP), were diminished after intervention
(Table 2). The most important changes were observed in
ALT, the initial prevalence of abnormal values was 47%;
and after intervention it decreased to 27%. No subject in
this study changed from normal value to abnormal value
after intervention.Effect of Dr. BAANs in Humans and Animals
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Table 1. Baseline characteristics of patients and changes in parameters after treatment
BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic blood pressure; AST = aspartate amino
transferase; ALT = alanine transaminase; γ-GTP = gamma glutamyl transpeptidase; TC = total cholesterol; LDL-
C = low density lipoprotein-cholesterol; HDL-C = high density lipoprotein-cholesterol; TG = triglyceride;
HbA1c = hemoglobin A1c; PAI-1 = plasminogen activator inhibitor-1. *p<0.05 vs before treatment
Variable
Mean ± SD
Before After Change
n =1 5 n =1 5
Age (years) 42.4 ± 9.3 42.4 ± 9.3
Height (m) 169.6 ± 9.4 169.6 ± 9.4
Weight (kg) 77.7 ± 12.6 76.5 ± 12.1* −1.2 ± 1.8
Waist circumference (cm) 92.2 ± 7.3 90.8 ± 6.4 −1.4 ± 3.9
BMI (kg/m2) 26.9 ± 2.4 26.5 ± 2.5* −0.4 ± 0.6
Body fat (%) 29.6 ± 4.3 26.4 ± 4.6* −3.2 ± 1.7
SBP (mmHg) 126.8 ± 19.7 119.6 ± 13.9* −7.2 ± 13.3
DBP (mmHg) 82.1 ± 15.4 77.1 ± 15.1 −5.0 ± 10.6
AST (IU) 26.8 ± 11.3 23.5 ± 7.2 −3.3 ± 6.7
ALT (IU) 35.7 ± 22.0 26.9 ± 12.9* −8.8 ± 12.2
γ GTP (IU) 71.9 ± 55.2 53.3 ± 37.0* −18.6 ± 22.6
TC (mg/dl) 228.6 ± 44.7 218.2 ± 35.5 −10.4 ± 21.7
LDL-C (mg/dl) 131.1 ± 41.4 123.7 ± 31.9* −7.4 ± 18.1
HDL-C (mg/dl) 59.9 ± 17.8 59.1 ± 18.1 −0.8 ± 6.3
TG (mg/dl) 164.2 ± 122.3 129.8 ± 78.8* −34.4 ± 67.0
Blood glucose (mg/dl) 96.9 ± 18.1 96.7 ± 21.2 −0.2 ± 10.0
HbA1c (mg/dl) 5.1 ± 0.5 5.0 ± 0.4 −0.1 ± 0.2
Adiponectin (μg/ml) 3.8 ± 4.2 4.3 ± 4.5* 0.58 ± 0.64
PAI-1 (ng/ml) 59.3 ± 37.1 44.0 ± 25.2* −14.3 ± 23.4
Table 2. Prevalence of abnormal values before and after treatment
SBP = systolic blood pressure; DBP = diastolic blood pressure; AST = aspartate amino transferase; ALT = alanine
transaminase; γ-GTP = gamma glutamyl transpeptidase; TC = total cholesterol; LDL-C = low density lipoprotein-
cholesterol; HDL-C = high density lipoprotein-cholesterol; TG = triglyceride; HbA1c = hemoglobin A1c.
Variable
Before (%) After (%)
n =1 5 n =1 5
Normal Abnormal Normal Abnormal
SBP 10 (67) 5 (33) 12 (80) 3 (20)
DBP 10 (67) 5 (33) 11 (73) 4 (27)
AST 14 (93) 1 (7) 15 (100) 0 (0)
ALT 8 (53) 7 (47) 11 (73) 4 (27)
γ GTP 8 (53) 7 (47) 9 (60) 6 (40)
TC 6 (40) 9 (60) 9 (60) 6 (40)
LDL-C 9 (60) 6 (40) 11 (73) 4 (27)
HDL-C 2 (13) 13 (87) 2 (13) 2 (13)
TG 9 (60) 8 (40) 11 (73) 4 (27)
Blood glucose 13 (87) 2 (13) 14 (93) 1 (7)
HbA1C 14 (93) 1 (7) 14 (93) 1 (7)K. Watanabe et al.
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On the other hand, when the effects of Dr. BAANs® on
hyperlipidemia prevalence were assessed, the initial
abnormal levels of TC, LDL-C, and TG were diminished
after treatment (Table 2). At the end of the treatment period
there were significant differences in LDL-C and TG levels
(Table 1 and Fig. 1c). While for blood glucose and HbA1c
values, no significant changes were observed throughout the
experimental period (Table 1). The metabolic syndrome
marker adiponectin (Fig. 1d) was increased significantly
(3.8 ± 4.2 μg/ml vs 4.3 ± 4.5 μg/ml,  p<0.05) while PAI-1
was decreased significantly (59.3 ± 37.1 ng/ml vs 44.0 ±
25.2 ng/ml, p<0.05).
In the overall safety assessment, no adverse events
(including nausea, vomiting, diarrhea, weakness, fatigue,
syncope) were noted in any of the subjects.
Fatty acid metabolism in animals
The uptake of 125I-labeled compound (%) into the tissues
is summarized in Table 3. The myocardial uptake at 10 min
after injection of 125I-9MPA was higher in obese mice than in
control mice. Treatment with Dr. BAANs® in obese mice
decreased the uptake significantly (Table 3). These results
were the same as found in other tissues (skeletal muscle, and
visceral and subcutaneous fat). The level of final product of
9-MPA metabolite, PIPA in those tissues were markedly
reduced in obese mice but recovered with treatment (Fig. 2
Fig. 1. Body mass index (BMI) (a), systolic blood pressure (SBP) (b), low density lipoprotein-cholesterol (LDL-C) (c) and adiponectin
(d) values in each subject from baseline until the end of intervention. Open square is value of each patient; close square is
average in each value.Effect of Dr. BAANs in Humans and Animals
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and 3). The ratio of 9MPA metabolites (3MNA + PIPA) to
9MPA non metabolites in myocardial tissue in obese mice
was significantly increased by treatment (Table 3). These
results indicate the recovery of the slower conversion of
metabolites following treatment.
Discussion
The aims of the present study were to evaluate whether or
not the food substitute (Dr. BAANs®) administered orally in
overweight patients may have efficacy to prevent or improve
metabolic syndrome after 3 months of treatment. After 3
months, comparing the initial and final data showed that the
parameters of metabolic syndrome criteria were improved,
while in the animal study the final product of 9-MPA
metabolite PIPA in obese mice was increased significantly
by treatment, indicating the recovery of the slower conver-
sion metabolites in obese mice.
This food substitute contains three bioactive components:
L-arginine,  ω-3 polyunsaturated fatty acid, and RNA.
Previous studies in animals and humans have demonstrated
the efficacy of dietary arginine supplementation, the physio-
logical precursor of nitric oxide (NO), in reducing the
mass in obese patients [12,  13]. Numerous studies have
demonstrated the beneficial effect of acute and chronic L-
arginine supplementation on endothelium derived nitric
oxide production and endothelial function. L-arginine has
also been shown to reduce systemic blood pressure in some
forms of experiments involving hypertension [14]. As a
precursor for the syntheses of NO, L-arginine plays pivotal
role in nutrition and metabolism. Arginine is classified as an
essential amino acid for young mammals, and conditionally
essential for adults, particularly at times of trauma and
disease. Some evidence also showed that enteral or
parenteral administration of arginine reverses endothelial
dysfunction associated with major cardiovascular risk
factors (hypercholesterolemia, smoking, hypertension, dia-
betes, obesity/insulin resistance, and aging), and ameliorates
many common cardiovascular disorders (coronary and
Table 3. Distribution of 125I radioactivity in tissues following 10 min intravenous injection of 125I-labeled 9MPA
Results are the means ± SD. *p<0.05 vs control; #p<0.05 vs ob/ob mice (without treatment)
Tissue
9MPA 3MNA PIPA 3MNA + PIPA/9MNA
%%%%
Myocardium
Control mice (n =3 ) 3 . 6± 1.2 17.9 ± 9.3 11.8 ± 1.2 8.3 ± 0.3
ob/ob mice (n = 3) 19.9 ± 0.3* 9.0 ± 0.7 1.3 ± 0.4* 0.5 ± 0.1*
ob/ob mice + Dr BAANs (n =3 ) 9 . 9± 2.5*# 6.6 ± 0.5 9.5 ± 3.2# 1.7 ± 0.6*#
Skeletal muscle
Control mice (n =3 ) 1 . 9± 0.4 4.2 ± 1.5 24.8 ± 3.0 16 ± 5.1
ob/ob mice (n = 3) 15.2 ± 2.6* 12.2 ± 1.3* 3.7 ± 0.3* 1.1 ± 0.2*
ob/ob mice + Dr. BAANs (n = 3) 12.2 ± 3.8* 10.2 ± 2.4* 24.8 ± 9.0# 3.2 ± 1.9*
Visceral fat
Control mice (n =3 ) 8 . 7± 0.4 5.9 ± 0.3 31.1 ± 7.1 4.2 ± 0.9
ob/ob mice (n =3 ) 1 0± 0.2* 4.1 ± 0.1* 1.6 ± 0.8* 0.5 ± 0.1*
ob/ob mice + Dr. BAANs (n =3 ) 5 . 0± 0.1*# 3.4 ± 0.7* 5.6 ± 0.8*# 1.7 ± 0.1*
Subcutaneous fat
Control mice (n =3 ) 1 . 8± 1.1 2.5 ± 1.8 4.1 ± 0.7 4.8 ± 3.1
ob/ob mice (n =3 ) 8 . 7± 0.4* 4.0 ± 0.1 2.3 ± 0.2 0.7 ± 0.01
ob/ob mice + Dr. BAANs (n =3 ) 6 . 1± 0.3*# 3.4 ± 0.5 7.8 ± 1.0*# 1.8 ± 0.3
Fig. 2. Representative examples of TLC analysis of 9MPA in
control, ob/ob, and ob/ob mice treated with Dr. BAANs®
at 10 min after 125I-9MPA injection. Summary of
radioactivity from intermediate metabolites above 9MPA
to PIPA were defined as metabolites processed by β-
oxidation.K. Watanabe et al.
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peripheral arterial disease, ischemia/reperfusion injury,
and heart failure) [15].
Another active component of this food supplement is ω-3
polyunsaturated fatty acid. Some epidemiological, observa-
tional, and randomized controlled clinical studies have
reported the beneficial effects of ω-3 polyunsaturated fatty
acid on cardiovascular disease [16]. It is known that
metabolic syndrome gives a 2 to 3 fold increased risk for
coronary heart disease, a similar risk for future ischemic
stroke, and a much greater risk for future diabetes [17].
The potential mechanism by which ω-3 fatty acid may
reduce the risk of cardiovascular disease involves reducing
the susceptibility of the heart to ventricular arrhythmia, and
promoting antithrombosis, nitric oxide-induced endothelial
relaxation and hypotriglyceridemic. ω-3 polyunsaturated
fatty acid also retard growth of atherosclerotic plague, and
may also have a small, dose-dependent hypotensive effect
[18, 19].
The third active component of Dr. BAANs® is RNA.
There are many food supplements on the market that contain
this component. RNA is synthesized endogenously and has
important effects on the growth and development of cells
that have a rapid turn over, such as those in the immune
system and the gastrointestinal tract. In healthy people
dietary nucleotides are probably not essential, and in fact
most will be metabolized and rapidly excreted from the
system. However, under certain circumstances (e.g. in the
sub-well, diseased, or under conditions of stress or poor diet)
dietary nucleotides may be semi-essential for optimizing the
function of the gastrointestinal and immune systems. The
dietary sources of nucleotides are nucleoproteins and nucleic
acid, and these are present at varying levels in food (but not
in fruit or vegetables). Rapidly dividing tissues require a
constant supply of nucleotides in order to manufacture
essential nucleic acids. Exogenous supplies of nucleotides
may optimize tissue function particularly during recovery
from mucosal injuries when the endogenous supply may
limit the synthesis of nucleic acids [20, 21].
In the previous study, Koide et al. [ 4] reported that
repetitive dosing of Dr. BAANs® in twenty test subjects
(metabolic syndrome patients or candidates) for one months
decreased body weight by 3.8 kg and reduced body fat by
2.4%. In the present study the same results were observed
that after 3-months intervention, body weight, BMI, and
percentage of body fat were reduced significantly. The
possible explanation for this result is that the components of
this food substitute may stimulate protein synthesis by
energy generated in the process of expediting the burn-off of
fatty acids, which results in the improvement of the intra-
vital metabolic cycle and protein synthesis.
In this study, comparing the initial and final data and the
prevalence of abnormal values before and after treatment,
improvements were observed in blood pressure (SBP:
7.2 ± 13.3 mmHg, DBP: 5.0 ± 10.6 mmHg decrease), lipid
profiles, and all items of hepatic functions (Tables 1 and 2).
As a result, metabolic syndrome in the all subjects was
observed to either improve significantly or tended to
improve. These results suggested that this food substitute
had a beneficial effect on blood pressure, hepatic function,
and lipid profiles.
The value of adiponectin in the blood, a marker of
metabolic syndrome, was significantly increased (0.58 ±
0.64 μg/ml) and the PAI-1 value was decreased significantly
(14.3 ± 23.4 μg/ml). From these results, it was anticipated
that adiponectin expression, which is a beneficial adipo-
cytokine, was increased in fat cells. This substance has been
reported to have anti-inflammatory and anti-atherogenic
properties [22]. Obese patients generally have low levels of
adiponectin and hence may be deprived of its protective
effects against metabolic syndrome [23,  24]. While the
levels of PAI-1, which is a non-beneficial adipocytokine,
were decreased. Circulating PAI-1 increases in obese
subjects with metabolic syndrome, as well as in patients
with type II diabetes [25]. The levels of PAI-1 were higher in
relation to metabolic syndrome. Interventional studies
reported that if insulin resistance is improved, plasma PAI-1
Fig. 3. The final product of 9-MPA metabolite PIPA in each tissue. White bar control mice, Black bar ob/ob mice, gray scale bar ob/ob
mice treated with Dr. BAANs®, * p<0.05 vs control; # p<0.05 vs ob/ob mice.Effect of Dr. BAANs in Humans and Animals
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levels decrease. Treatment with insulin-sensitizing drugs
like metformin or thioglitazone decrease plasma PAI-1
levels in subjects with type II diabetes and to some extent in
normal obese subjects [26, 27].
In support of the present clinical study, evaluation of the
fatty acid metabolism in vivo in obese mice was also
performed and compared with obese mice treated by the
food substitute Dr. BAANs® by analysis of the distribution
of an 125I-labeled metabolite in the lipid pools of various
tissues. In myocardium, skeletal muscle, visceral and
subcutaneous fat, the final product of 9-MPA metabolite
PIPA in obese mice was significantly increased by the
dietary intervention, and it was indicated that this dietary
supplement enhanced fatty acid β-oxidation in these tissues.
The slower conversion in the obese mice was compatible
with the very poor myocardial β-oxidation activity of
palmitic acid. In this animal study, we fed the food substitute
to the mice for only one week because we realize that body
weight may be reduced after long dietary intervention in
obese animals and thus results will not be reliable.
Finally, the safety of this dietary supplement in this
human study was demonstrated by the absence of the eleva-
tion of AST levels throughout the evaluation period and also
lack of reports of adverse effects in the population studied.
In conclusion, the present results demonstrate that this
food substitute, which contains L-arginine, ω-3 polyunsatu-
rated fatty acids, and RNA, may have a beneficial effect on
the prevention or improvement of metabolic syndrome.
These results suggest that this food substitute could be used
as a supplement for overweight patients to prevent or
improve metabolic syndrome; however, these findings
deserve more research in view that the present study was
performed in a small number of subjects and the short
duration of the study.
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